by Backoffice | Jan 4, 2024 | Collaborations
In Europe, approximately 30 million people suffer from blindness and visual impairment. Rare Eye Diseases are a major cause that can result in blindness in children and young adults and affect adults and the ageing population. Current management is expensive, has low...
by Backoffice | Nov 3, 2023 | Studies and testing
The first two children with autism spectrum disorder (ASD) and signs of leaky gut syndrome were treated October 2023 with allogeneic adipose-derived mesenchymal stem cells (C2C_ASCs) at Aalborg University Hospital without any complication. The project is a...
by Backoffice | Oct 18, 2023 | Patents
As of the 18th of September 2023, the patent secures C2Cs technological concept for industrial production, upscaling, and distribution of ASC products has been granted in Canada (Patent number: 3000912). The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM...
by Backoffice | May 25, 2023 | Collaborations
Cell2Cure has developed a stem cell product that does not require a tissue match between donor and patient and can simply be stored in the freezer for use in various clinical purposes. Cell2Cure was in continuation of the pres release visited – and researched...
by Backoffice | Apr 18, 2023 | Studies and testing
Patient with severe terminal lung disease may ultimately be treated with a donor lung transplantation. However, transplantation of a lung from another person elicits a strong immunologic reaction by the recipient towards the transplanted donor lung. In the worst case,...
